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shocks but secondary prevention patients showed a higher rate of appropriate 
therapy.
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Objectives: Identify patient and clinical characteristics in the diabetic foot ulcer 
(DFU) population and examine patterns of cellular/tissue derived product (CTP) 
utilization. MethOds: Retrospective, de-identified electronic medical records 
from 2007-2013 were extracted from the Intellicure Limited Data Set (I-LDS). The 
I-LDS extracts records from 96 hospital-based outpatient wound centers. Patient, 
wound and encounter level characteristics were examined. CTPs of interest included 
extracellular matrix (ECM), human skin equivalent (HSE), and living skin equivalent 
(LSE). Results: A total of 10,359 patients, 21,677 wounds, and 222,861 encoun-
ters for DFU were identified. The majority of patients was male (60.9%), Caucasian 
(63.5%), and reported Medicare as their primary insurance (51.1%). The average age 
was 63.9 (SD= 13.5) and the average number of physician visits was 17.4 (SD= 20.8). 
The mean wound surface area was 5.6 cm2 (SD= 27.3). The overall average wound 
age was 7.0 months (SD= 16.26). Of the 21,677 wounds, approximately 8.6% received 
ECM (2.6%), HSE (2.6%), or LSE (3.4%). The average number of applications for ECM 
was 2.7 (SD= 2.5), 2.0 (SD= 1.7) for HSE, and 4.0 (SD= 2.9) for LSE. Wounds treated with 
CTPs were, on average, several months older relative to the overall DFU population: 
16.0, 16.4, and 14.7 months for ECM, HSE, and LSE, respectively. Overall average 
wound treatment time was 3.4 months (SD= 8.4). However, treatment time was 
substantially longer with CTP utilization with an average time of 9.1, 9.3, and 8.0 
months for ECM, HSE, and LSE, respectively. cOnclusiOns: CTP utilization was 
relatively low within outpatient wound centers. Results from this analysis indicate 
that health care providers are using CTPs on older, more difficult-to-heal DFUs.
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Objectives: Identify patient and clinical characteristics in the DFU population 
and examine patterns of hyperbaric oxygen therapy (HBOT), negative pressure 
wound therapy (NPWT), and becaplermin gel utilization. MethOds: Retrospective, 
de-identified electronic medical records from 2007-2013 were extracted from the 
Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 hospital-
based outpatient wound centers. Patient, wound and encounter level character-
istics were examined. Utilization of advanced therapies including HBOT, NPWT, 
and becaplermin gel were analyzed. Results: A total of 10,359 patients, 21,677 
wounds, and 222,861 encounters for DFU were identified. The majority of patients 
was male (60.9%), Caucasian (63.5%), and reported Medicare as their primary insur-
ance (51.1%). The average age was 63.9 (SD= 13.5) and the average number of evalua-
tion and management visits was 21.9 (SD= 26.9). Mean wound surface area was 5.6 
cm2 (SD= 27.3). Of the 10,359 patients, approximately 28.2% received HBOT, 16.0% 
received NPWT, and 4.1% received becaplermin gel. Average number of HBOT visits 
was 31.7 (SD= 24.9) and 1.2 (SD= 0.6) episodes for NPWT. The average number of 
becaplermin days was 81.7 (SD= 113.2). Of the 21,677 wounds, the overall average 
wound treatment time was 3.4 months (SD= 8.4). The reported risk of amputation 
was lower in wounds treated with becaplermin (3.3%) compared to the overall popu-
lation (5.3%), problems treated with NPWT (5.6%) and HBOT (9.8%), respectively. 
Wounds treated with becaplermin were more likely to heal (46.3%) relative to the 
overall population (41.1%), problems treated with NPWT (27.5%) and HBOT (32.2%), 
respectively. cOnclusiOns: Advanced therapy utilization varied within outpatient 
wound centers. Results from this analysis indicate that health care providers are 
using advanced therapies on difficult-to-heal DFUs.
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Objectives: Evidence for surveillance intervals of colonoscopy are primarily 
based on adenoma recurrence rather than on CRC incidence. Current evidence 
suggests that due to the overuse of surveillance colonoscopy among low-risk 
patients and the underuse among high-risk patients the recommended surveil-
lance intervals may need adjustment. This study aims to tailor surveillance inter-
vals by estimating incidence of CRC at subsequent colonoscopy under diverse 
circumstances. MethOds: A population-based, retrospective cohort study of 
patients with a colonoscopy between January 2010 and March 2014 were identi-
fied in a well-administrated database of colonoscopy screening and surveillance. 
The data includes patient demographics, family history of CRC, and the pathology 
result (including date) of previous and current colonoscopies. Adjusted Weibull 
regression models estimated the incidence rate of CRC at subsequent colonos-
copy given any proper interval and risk (level and coexisting). Levels of risk for 
patients without CRC, based on baseline colonoscopy, were: High Risk (≥ 3, large 
or advanced adenoma), Medium risk and Low risk (no polyp). Coexisting risk was 
defined by a combination of two the three levels: a) an incomplete polyp removal, 
b) a ≥ 3 adenoma at last colonoscopy, c) a personal history of CRC. Results: 
Among total 27,325 patients, the prevalence of CRC at baseline colonoscopy was 
8.2% for the patients with follow-up. The benchmark risk was determined by the 
overall interval incidence of CRC (0.33%) for low risk patients. Men and women 
with high risk or CRC history exceeded this benchmark in approximately 5 and 10 
Objectives: Implantable cardioverter defibrillator (ICD) is considered a lifelong 
therapy for the prevention of sudden cardiac death. However, it is still unresolved 
if patients who never experienced an appropriate ICD intervention during first gen-
erator longevity really need to undergo device replacement. MethOds: In a single-
center prospective observational cohort study we examined the time-dependence of 
first appropriate ICD therapy for ventricular arrhythmias in patients who underwent 
ICD implantation for primary prevention. Primary prevention ICD patients were 
enrolled at the time of their first implantation and were evaluated thereafter for the 
first occurrence of appropriate ICD therapy for ventricular arrhythmias. Results: 
Of 623 ICD recipients, 126 (20,2%) had appropriate ICD therapy. Incidence of first 
appropriate ICD therapy was 8.2% in the first year post-implant, increased to 13.7% 
in year 2, while in year 5 it was 28.3% (fig 1). Notably 39 patients received their 
first appropriate therapy after device replacement. No predictive factors for lower 
need of ICD therapy could be identified in patients without prior appropriate ICD 
intervention. cOnclusiOns: In a primary prevention population the risk of first 
appropriate ICD therapy persists over long lifetime and necessitates continuing 
device therapy irrespective of shock-free intervals.
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Objectives: We investigated prospectively whether serum markers of collagen 
turnover could be used as predictors for the occurrence of malignant ventricu-
lar arrhythmias in patients with non-ischemic dilated cardiomyopathy (NIDC) 
implanted with an implantable cardioverter defibrillator (ICD) for primary preven-
tion. Extracellular matrix (ECM) alterations in NIDC may provide electrical hetero-
geneity, thus potentially contributing to the occurrence of ventricular arrhythmia 
and subsequent SCD. MethOds: Serum C-terminal propeptide of collagen type-I 
(CICP), C-terminal telopeptide of collagen type-I (CITP), matrix metalloproteinase 
(MMP)-1, and tissue inhibitor of matrix metalloproteinases (TIMP)-1 were measured 
as markers of collagen synthesis and degradation in 70 patients with mildly to 
moderate symptomatic heart failure due to NIDC with LVEF < 35%, who received 
an ICD for primary prevention of SCD. Patients were evaluated for any appropriate 
ICD delivered therapy, whether shock or antitachycardia pacing, during a 1-year 
follow-up period. Results: Appropriate device therapies were delivered in 14 of the 
70 patients during the follow-up period, with antitachycardia pacing in 2, antitachy-
cardia pacing with shocks in 4, and shocks in 8. Preimplantation MMP-1 levels were 
significantly higher in patients who had appropriate ICD-delivered therapy than 
in those who did not have any therapy (27.7±1.6 ng/ml vs. 24.1±2.5 ng/ml, respec-
tively, p< 0.001). The same was true for baseline serum concentrations of TIMP-1 
and CITP (89±14 ng/ml vs. 58±18 ng/ml, p= 0.008 and 0.46±0.19 ng/ml vs. 0.19±0.07 
ng/ml, p< 0.001, respectively). cOnclusiOns: Undoubtedly, ECM alterations play a 
crucial role in the constitution of an arrhythmogenic substrate in NIDC and, given 
the availability of therapies to prevent fatal ventricular tachyarrhythmias, the quest 
for factors that have a very good correlation with appropriate ICD discharges in 
these patients is logical. Our results confirm the role of serum markers of collagen 
turnover as predictors of arrhythmic events in ICD recipients and could provide an 
auxiliary tool in this context.
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Objectives: The beneficial effects of implantable cardioverter defibrillators (ICDs) 
in primary and secondary prevention patients are well established. However, 
relative scarcity of data exists regarding long-term follow-up outcomes of this 
population in the context of tertiary hospitals-ICD implantation centres beyond 
randomized clinical trials borders. The aim of the study was to exhibit “real-world” 
data and possible differences on mortality and ICD therapies between secondary 
and primary prevention ICD recipients. MethOds: All patients treated with an 
ICD, regardless of the underlying cardiac pathology, at the island of Crete were 
included in the current analysis. The study population was grouped by the type of 
prevention (secondary or primary) for sudden cardiac death. The primary endpoint 
was all-cause mortality. The secondary endpoint was the occurrence of device 
therapy (appropriate or inappropriate). Results: A total of 854 (88.6% men) ICD 
recipients were included. Of these, 623 (73%) patients received an ICD for pri-
mary prevention of sudden cardiac death and 231 (27%) patients for secondary 
prevention. During a mean follow-up of 12,4 +/-7,8 years, 177 (20.7%) patients 
died. The incidence of mortality was 35,5% for secondary prevention patients and 
15.2% for primary prevention patients (p< 0.001). Ventricular arrhythmia triggered 
appropriate therapy in 91 (39,4%) secondary prevention patients. Accordingly the 
number of primary prevention patients that received appropriate therapy was 126 
(20,2%). A comparable risk for inappropriate shocks was observed. cOnclusiOns: 
During long-term follow-up, primary prevention patients exhibited a lower risk 
for all-cause mortality. Both groups showed similar occurrence of inappropriate 
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years. 2015 Medicare deductibles and co-insurance rates were used to estimate 
spend for LAAC, acute clinical events and office visits. Average drug costs were 
calculated from the four states with the largest number of Medicare beneficiar-
ies. Patient stay days were taken from HCUP and inpatient rehabilitation prospec-
tive payment system data. Clinical probabilities for LAAC and warfarin were taken 
from PROTECT AF 4-year data and for dabigatran from the RE-LY trial. Results: 
The deductible for the LAAC procedure was $1,260. This compares to an average 
annual acquisition cost of roughly $345 for warfarin and $1,048 for dabigatran. First 
year total costs were $1,734, $1,023 and $1,335, for LAAC, warfarin and dabigatran, 
respectively. By the end of year 2, LAAC was less expensive with total costs of $2,353 
compared to $2,702 (warfarin) and $2,865 (dabigatran). By year 5, LAAC was approxi-
mately half the cost of anticoagulants. cOnclusiOns: Patient out-of-pocket costs 
for stroke prevention in AF are considerable and may represent a burden for many 
Medicare beneficiaries living on fixed incomes. LAAC with the Watchman Device 
provides lifetime stroke prophylaxis without increased bleeding risk at a lower 
cost to patients.
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Objectives: Bleeding in liver surgery can be difficult to control due to extreme 
vascularity and tissue fragility, including compromised liver (e.g., cancer). Blood 
loss may be minimized with hemostats that have rapid effect and may impact cost 
of care. This study estimated budget impact of using EVARREST vs. SoC in hepatic 
surgery based on two randomized trials. MethOds: An economic analysis was 
developed to quantify 30-day cost impact of EVARREST from a U.S. hospital per-
spective. Key resources, from two randomized trials (n=180), included initial treat-
ment, retreatment, operating time, transfusions, ventilator, and hospitalization. 
Transplant patients (n=6) where normal liver tissue was resected were excluded 
from analyses.  SOC was composed mainly of manual compression alone or with 
hemostats. The surgical analysis included resources clinically related to significant 
hemostasis benefits of EVARREST (i.e. retreatment, operating time, transfusion). A 
hospital analysis included all resources collected. Economic analyses were com-
pleted for the following subgroups: abnormal liver, metastatic cancer, anatomic/
non-anatomic liver (classifications using IHPBA definitions), cirrhotic/steatotic liver, 
and if patients were obese or coagulopathic. Published U.S. costs were applied to 
resource use. Analysis results were weighted based on trial size. Results: The 
surgical analysis predicted that the EVARREST cost was offset vs. SoC with a trial-
weighted cost impact of $719 per patient.  The hospital analysis predicted further 
resource reduction with EVARREST with trial-weighted cost-savings of $868 per 
patient.  Subgroup analyses demonstrated a range of results from cost impact to cost 
savings with EVARREST vs. SOC (i.e., $1,976 to -$5,430 per patient, hospital analysis). 
EVARREST use in coagulopathic patients was found to have the largest degree of 
cost savings with $1,859 and $5,176 per patient anticipated, surgical and hospital 
results respectively. cOnclusiOns: In addition to meeting an important unmet 
need in controlling problematic bleeding in liver tissue, this analysis suggests that 
EVARREST can be a cost saving strategy.
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Objectives: Anti-epidermal growth factor receptor (EGFR) therapies are ineffective 
in tumors with KRAS mutations in exon 2 codons 12 and 13. Thus, guidelines have 
recommended determination of KRAS mutation status in metastatic colorectal can-
cer (mCRC). Both the cobas® KRAS Mutation Test (cobas® test, currently available as 
Research Use Only in the US) and the therascreen KRAS RGQ PCR Kit (therascreen 
test) detect KRAS mutations in exon 2; cobas® test detects twelve mutations and 
therascreen test detects seven mutations in exon 2. We estimated the potential 
clinical and budgetary impact of using the cobas® test versus therascreen test in 
the mCRC setting. MethOds: A budget impact model comparing the clinical and 
economic outcomes of using the cobas® test versus therascreen test was devel-
oped from the US payer perspective. We assumed 42,000 annual cases of mCRC 
patients. Model inputs were obtained from literature, whereas testing and treat-
ment costs were calculated from CMS reimbursement rates. KRAS test sensitivity 
reflected the test’s ability to detect mutations in codons 12 and 13; specificity was 
assumed to be the same for both tests. The model calculated the average cost for 
mCRC patients over 5 years, using median time on treatment and median overall 
survival. Based on current practice patterns, the proportion of patients receiving 
KRAS testing before 1st-line, 2nd-line, and 3rd-line therapy were 42%, 32%, and 
26%, respectively. Results: Adopting the cobas® test resulted in a reduction of 289 
patient-months lost due to non-optimal care (i.e. by avoiding anti-EGFR therapies in 
mutant positive patients) and an improvement in median overall survival. Adopting 
the cobas® test generated a total of $2.3 million in cost savings and an average 
decrease of $7 per mCRC patient per month. cOnclusiOns: Using the cobas® test 
with improved sensitivity was associated with a reduction of patient-month lost 
and a decrease of healthcare costs in mCRC patients.
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years, while low risk patients exceeded it in 15 years, respectively. Coexisting risk 
resulted in a sharp increase in the incidence of CRC exceeding the benchmark risk 
in less than 3 years. cOnclusiOns: Intervals based on incidence of CRC diverge 
from adenoma only surveillance recommendations and suggest a longer interval 
of follow-up except for those with co-existing risk.
MeDical Device/DiagnosTics - cost studies
PMD13
buDgeT iMPacT MoDel of a blooD baseD ProTeoMic classifier for 
inDeTerMinaTe PulMonary noDules
Aggarwal J.1, Goss T.2, Mathews C.1, Kearney P.3, Diette G.4
1Boston Healthcare, Boston, MA, USA, 2Boston Healthcare Associates, Boston, MA, USA, 3IndiDx, 
Seattle, WA, USA, 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Objectives: Depending on the penetration of screening recommendations, it is 
possible that the incidence of detected pulmonary nodules (PNs) could increase 
exponentially in coming years. Currently PN evaluation routinely requires costly 
procedures including imaging, biopsy and surgery. A molecular blood based test that 
measures plasma proteins using selected reaction monitoring mass spectroscopy 
allows for an objective and quantitative assessment of PN benignity. This budget 
impact analysis was performed to quantify the molecular test impact on a US com-
mercial health plan’s direct medical costs. MethOds: The budget impact model 
was developed from a commercial health plan perspective, with direct medical costs 
estimated from the MarketScan® reimbursement benchmark data. Total PN diag-
nostic evaluation costs were estimated for a 2-year time horizon and were calculated 
for the current standard of care and care with the introduction of the molecular 
test. Diagnostic procedure resource utilization was obtained from a retrospective 
chart review analysis of a geographically representative sample of indeterminate 
PNs (8-20mm) managed by outpatient pulmonologists. Results: Currently, 52% 
of PNs are evaluated with an invasive procedure (biopsy/surgery) and 48% with 
surveillance alone, with significant cost differences observed between these two 
groups. The base case analysis using a health plan of one million members and a 
rate of 0.25% PNs within the health plan, estimated a 27% reduction in avoidable 
invasive procedures with the introduction of the molecular test. This amounted 
to a total potential cost savings of 20% from procedure and complication avoid-
ance. cOnclusiOns: Adoption of this molecular test may help reduce the number 
of unnecessary invasive procedures being performed for individuals presenting with 
indeterminate pulmonary nodules. The reduced resource utilization can result in 
cost savings for the health plan.
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Objectives: There is a strong correlation between cardiovascular disease and dia-
betes with management of blood pressure (BP), blood glucose (BG), and lipids being 
essential to preventing disease progression and complications. The FDA-cleared 
Proteus device captures and shares information about medication-taking, rest and 
activity patterns through a mobile device and app, a patch with a wearable sensor 
inside, and sensor-enabled pills. This offering facilitates patient engagement and 
behavioral change, informative provider decision-making, and improvement of out-
comes. An economic model was developed to estimate the impact of reducing BP, 
BG, and lipids via the Proteus offering. MethOds: The value of 1-month use of the 
Proteus offering to reduce BP, BG, and lipids was evaluated in patients with comorbid 
hypertension, type 2 diabetes, and hypercholesterolemia from a US payer perspec-
tive for a 1-year time horizon. The clinical and utilization assumptions were derived 
from the literature, expert opinion, and a real-world Proteus study in patients with 
uncontrolled hypertension. Costs were derived from the Medicare Fee Schedule 
and AHRQ databases. Payers were also interviewed for current management of 
these conditions as input to the model. Results: The cost offsets of the Proteus 
service offering were estimated to be $90-185 per month of use, including current 
reimbursement for medications and medication adherence solutions. Medical cost 
savings consisting of reductions in outpatient and inpatient services, monitoring, 
disease management, and medication costs were estimated to be $850-980 per 
patient per year (PPPY), which was mainly driven by a 5-11% reduction in diabetes 
and CVD complications. Revenue opportunities via meeting quality measures pre-
sented an additional value equating to $80-95 PPPY, bringing the total value of the 
Proteus offering to $1020-1260 PPPY. cOnclusiOns: The Proteus offering provides 
opportunities to mitigate the high costs of managing at-risk patients with multiple 
cardiometabolic comorbidities.
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Objectives: Healthcare costs today are increasingly being shifted from payers to 
patients, yet few providers factor patient costs into treatment decisions. Recent 
advancements in stroke prevention in atrial fibrillation (AF) have resulted in new 
treatment options where previously there were few. While the clinical benefit and 
cost effectiveness of these treatments are supported by a growing body of evi-
dence, the cost impact to patients has not been explored. This analysis sought to 
quantify patient out-of-pocket costs for three stroke prevention strategies: war-
farin, dabigatran and left atrial appendage closure (LAAC) with the Watchman 
Device. MethOds: A patient-level budget impact model was used to assess total 
out-of-pocket spend on treatment and treatment-related complications over five 
